JOHNSON JOHN
SEC Form 4 insider trading activity
JOHNSON JOHN has filed 6 SEC Form 4 filings (13 transaction rows) across 3 companies, including AXGN, XERS, VSTM, with disclosures dating back to 2025. 6 of those filings fall inside the rolling window. Most recent filing: Jun 23, 2026.
On the most recent filing, JOHNSON JOHN is listed as Director at Xeris Biopharma Holdings, Inc. Inside the rolling window, JOHNSON JOHN reported no open-market purchases and 5 open-market sales totaling $2.9M in XERS and AXGN. The largest disclosed transaction in the window is a sale of 135,400 XERS shares on Dec 19, 2025, worth $977K.
Companies traded
Other insiders at AXGN
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$2.9M
reported sales (SEC code S)
Companies
3
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has JOHNSON JOHN made?
JOHNSON JOHN has filed 6 SEC Form 4 filings (13 transaction rows) across 3 companies, including AXGN, XERS, VSTM since 2025.
Which companies does JOHNSON JOHN trade?
JOHNSON JOHN has filed SEC Form 4 disclosures for 3 companies, including AXGN, XERS, VSTM.
When was JOHNSON JOHN's most recent SEC Form 4 filing?
JOHNSON JOHN's most recent SEC Form 4 filing on Tracefour is dated Jun 23, 2026.
What is JOHNSON JOHN's total buy and sell value in the current window?
Inside the rolling retention window, JOHNSON JOHN bought $0 and sold $2.9M based on SEC Form 4 filings.
What was JOHNSON JOHN's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 135,400 XERS shares on 2025-12-19, worth $977K, per SEC Form 4 filings.